Key Highlights

  • WVE reported third-quarter revenue of $13.2 million, up from $7.6 million a year earlier.
  • The net loss was $61.9 million, or $0.30 per share, compared with $53.9 million, or $0.32, a year ago.
  • Cash, cash equivalents and marketable securities were $431.0 million, excluding a $12 million GSK milestone.
  • Research and development expense rose to $53.8 million from $45.9 million.
  • Management expects cash to fund operations into the third quarter of 2028.

Wave Life Sciences Earnings: What Does FDA Alignment on WVE-006 Mean for the Runway?

Wave Life Sciences (NASDAQ:WVE) reported third-quarter results on Tuesday, October 27, with revenue of $13.2 million, up from $7.6 million, and a net loss of $61.9 million, or $0.30 per share. A year earlier the loss was $53.9 million, or $0.32 per share. The earnings screen showed a loss of $0.30 against $0.32 expected, as screened.

Management said cash, cash equivalents and marketable securities were $431.0 million at September 30, which excludes a $12 million milestone from GSK (NYSE:GSK), and that this funds operations into the third quarter of 2028. Potential future GSK milestones are not included in that runway.

Wave develops RNA medicines, including GalNAc-conjugated siRNA and RNA-editing candidates aimed at obesity, alpha-1 antitrypsin deficiency and liver disease.

Spending and Cash: How Fast Is the Balance Sheet Shrinking?

Total operating expenses rose to $79.2 million from $64.0 million. Research and development was $53.8 million versus $45.9 million, and general and administrative expense was $25.4 million versus $18.1 million. Interest income doubled to $4.4 million, and the loss from operations was $66.0 million.

Over nine months, revenue was $53.7 million against $25.5 million, and the net loss was $157.4 million, or $0.78 per share, against $151.2 million, or $0.92. Cash and equivalents were $602.1 million at December 31, 2025, so liquidity has fallen by about $171 million as calculated.

WVE-006 and WVE-007: Which Catalysts Land in the Fourth Quarter?

In October, the FDA aligned with Wave on a registrational path for WVE-006, its RNA-editing candidate for alpha-1 antitrypsin deficiency. The agency supports a two-year registrational trial for potential full approval, with a one-year interim analysis that could support accelerated approval based on biomarkers. Data from the 600 mg monthly multidose cohort are expected in the fourth quarter.

For WVE-007, the obesity candidate, the Phase 2a monotherapy trial is dosing patients with a body mass index of 35 to 50, and a placebo-controlled combination study with weekly tirzepatide has started at 240 mg and 400 mg doses. Phase 1 600 mg single-dose data and the start of a post-incretin maintenance trial are expected in the fourth quarter.

For WVE-008, aimed at PNPLA3 liver disease, a clinical trial application is expected in the fourth quarter.

GSK Collaboration: How Much Revenue Could the Partnership Add?

In September, GSK selected a hepatology development candidate built on Wave's siRNA design, which earned Wave a $12 million milestone. Receipt of the cash is expected in the fourth quarter. Three additional collaboration programs are advancing toward candidate selection, and each program carries up to $330 million to $375 million in potential development, launch and commercial milestones plus tiered royalties.

What to Watch Next: Research Day and Four Fourth-Quarter Readouts

Wave holds a virtual research day on Wednesday, November 4. The fourth-quarter list is WVE-006 multidose data, WVE-007 600 mg data and maintenance trial start, the WVE-008 trial application, and receipt of the GSK milestone.